Cannabis use is associated with lower retention in methadone maintenance treatment, but not among schizophrenic- and other chronically psychotic patients

References

• Weizman T, Gelkopf M, Melamed Y, Adelson M, Bleich A. Cannabis abuse is not a risk factor for treatment outcome in methadone maintenance treatment: a 1-year prospective study in an Israeli clinic. Aust N Z J Psychiatry. 2004;38(1-2):42–6. doi:10.1046/j.1440-1614.2003.01296.x.
   PubMed Web of Science ®Google Scholar
• Epstein DH, Preston KL. Does cannabis use predict poor outcome for heroin-dependent patients on maintenance treatment? Past findings and more evidence against. Addiction. 2003;98(3):269–79. doi:10.1046/j.1360-0443.2003.00310.x.
   PubMed Web of Science ®Google Scholar
• Budney AJ, Bickel WK, Amass L. Marijuana use and treatment outcome among opioid-dependent patients. Addiction. 1998;93(4):493–503. doi:10.1046/j.1360-0443.1998.9344935.x.
   PubMed Web of Science ®Google Scholar
• Zielinski L, Bhatt M, Sanger N, Plater C, Worster A, Varenbut M, Daiter J, Pare G, Marsh DC, Desai D, et al. Association between cannabis use and methadone maintenance treatment outcomes: an investigation into sex differences. Biol Sex Differ. 2017;8:8. doi:10.1186/s13293-017-0130-1.
   PubMed Web of Science ®Google Scholar
• Rosic T, Naji L, Bawor M, Dennis B, Plater C, Marsh D, Thabane L, Samaan Z. The impact of comorbid psychiatric disorders on methadone maintenance treatment in opioid use disorder: a prospective cohort study. NDT. 2017;13:1399–408. doi:10.2147/NDT.S129480.
   Google Scholar
• Fan CY, Tan HK, Chien IC, Chou SY. Prevalence of psychiatric disorders among heroin users who received methadone maintenance therapy in Taiwan. Am J Addict. 2014;23(3):249–56. doi:10.1111/j.1521-0391.2014.12090.x.
   PubMed Web of Science ®Google Scholar
• Fernández Miranda J, González García-Portilla M, Sáiz Martínez P, Gutiérrez Cienfuegos E, Bobes García J. Influence of psychiatric disorders in the effectiveness of a long-term methadone maintenance treatment. Actas Esp Psiquiatr. 2001;29(4):228–32.
   PubMed Web of Science ®Google Scholar
• Peles E, Schreiber S, Domany Y, Adelson M. Impact of lifetime psychiatric diagnosis on long-term retention and survival of former opiate addicts in methadone maintenance treatment. World J Biol Psychiatry. 2014;15(8):629–35. doi:10.3109/15622975.2014.942359.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Hall W. Is cannabis use a contributory cause of psychosis?Can J Psychiatry. 2006;51(9):556–65. doi:10.1177/070674370605100903.
   PubMed Web of Science ®Google Scholar
• Misiak B, Stramecki F, Gawęda Ł, Prochwicz K, Sąsiadek MM, Moustafa AA. Interactions between variation in candidate genes and environmental factors in the etiology of schizophrenia and bipolar disorder: A systematic review. Mol Neurobiol. 2017;55(6):5075–5100.
   PubMed Web of Science ®Google Scholar
• Foglia E, Schoeler T, Klamerus E, Morgan K, Bhattacharyya S. Cannabis use and adherence to antipsychotic medication: a systematic review and meta-analysis. Psychol Med. 2017;47(10):1691–705. doi:10.1017/S0033291717000046.
   PubMed Web of Science ®Google Scholar
• Schoeler T, Petros N, Di Forti M, Klamerus E, Foglia E, Murray R, Bhattacharyya S. Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis. Lancet Psychiatry. 2017;4(8):627–33. doi:10.1016/S2215-0366(17)30233-X.
   PubMed Web of Science ®Google Scholar
• Ringen PA, Vaskinn A, Sundet K, Engh JA, Jónsdóttir H, Simonsen C, Friis S, Opjordsmoen S, Melle I, Andreassen OA, et al. Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia. Psychol Med. 2010;40(8):1337–47. doi:10.1017/S0033291709991620.
   PubMed Web of Science ®Google Scholar
• Scholes KE, Martin-Iverson MT. Cannabis use and neuropsychological performance in healthy individuals and patients with schizophrenia. Psychol Med. 2010;40(10):1635–46. doi:10.1017/S0033291709992078.
   PubMed Web of Science ®Google Scholar
• Bahorik AL, Newhill CE, Eack SM. Neurocognitive functioning of individuals with schizophrenia: using and not using drugs. Schizophr Bull. 2014;40(4):856–67. doi:10.1093/schbul/sbt099.
   PubMed Web of Science ®Google Scholar
• Rabin RA, Zakzanis KK, George TP. The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis. Schizophr Res. 2011;128(1-3):111–6. doi:10.1016/j.schres.2011.02.017.
   PubMed Web of Science ®Google Scholar
• Kreek MJ. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci. 2000; 909:186–216. doi:10.1111/j.1749-6632.2000.tb06683.x.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;6(2):CD002207. doi:10.1002/14651858.CD002207.pub4.
   Google Scholar
• Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, Fry-Smith A, Day E, Lintzeris N, Roberts T, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007;11(9):1–171. doi:10.3310/hta11090.
   PubMed Web of Science ®Google Scholar
• Adelson M, Linzy S, Peles E. Characteristics and outcome of male and female methadone maintenance patients: MMT in Tel Aviv and Las Vegas. Subst Use Misuse. 2017; 2:1–9.
   Google Scholar
• Peles E, Schreiber S, Adelson M. 15-Year survival and retention of patients in a general hospital-affiliated methadone maintenance treatment (MMT) center in Israel. Drug Alcohol Depend. 2010;107(2-3):141–8. doi:10.1016/j.drugalcdep.2009.09.013.
   PubMed Web of Science ®Google Scholar
• Peles E, Schreiber S, Sason A, Adelson M. Similarities and changes between 15- and 24-year survival and retention rates of patients in a large medical-affiliated methadone maintenance treatment (MMT) center. Drug Alcohol Depend. 2018;185:112–9. doi:10.1016/j.drugalcdep.2017.11.034.
   PubMed Web of Science ®Google Scholar
• Naji L, Dennis BB, Bawor M, Plater C, Pare G, Worster A, et al. A prospective study to investigate predictors of relapse among patients with opioid use disorder treated with methadone. Subst Abuse. 2016;10:9–18.
   PubMed Web of Science ®Google Scholar
• Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. 2008;165(2):179–87. doi:10.1176/appi.ajp.2007.06111851.
   PubMed Web of Science ®Google Scholar
• Calsyn DA, Saxon AJ. An innovative approach to reducing cannabis use in a subset of methadone maintenance clients. Drug Alcohol Depend. 1999;53(2):167–9. doi:10.1016/S0376-8716(98)00121-5.
   PubMed Web of Science ®Google Scholar
• Peles E, Schreiber S, Sason A, Adelson M. Earning “take-home” privileges and long term outcome in a methadone maintenance treatment program. J Addict Med. 2011;5(2):92–8. doi:10.1097/ADM.0b013e3181e6ad48.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed.Washington, DC: American Psychiatric Press, APA; 2000.
   Google Scholar
• McLellan AT, Luborsky L, O’Brien CP, Barr HL, Evans F. The Addiction Severity Index in three different populations. NIDA Res Monogr. 1984;55:217–23.
   PubMedGoogle Scholar
• Hawks RL. Analytical methodology. NIDA Res Monogr. 1986;73:30–42.
   PubMedGoogle Scholar
• Rodríguez-Sánchez JM, Ayesa-Arriola R, Mata I, Moreno-Calle T, Perez-Iglesias R, González-Blanch C, Periañez JA, Vazquez-Barquero JL, Crespo-Facorro B. Cannabis use and cognitive functioning in first-episode schizophrenia patients. Schizophr Res. 2010;124(1-3):142–51. doi:10.1016/j.schres.2010.08.017.
   PubMed Web of Science ®Google Scholar
• Abrahamsson T, Berge J, Öjehagen A, Håkansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study . Drug Alcohol Depend. 2017;174:58–64. doi:10.1016/j.drugalcdep.2017.01.013.
   PubMed Web of Science ®Google Scholar
• Mayet A, Lions C, Roux P, Mora M, Maradan G, Morel A, Michel L, Marimoutou C, Carrieri MP. Variations in cannabis use level and correlates in opiate-users on methadone maintenance treatment: A French prospective study. J Subst Abuse Treat. 2015;58:100–5. doi:10.1016/j.jsat.2015.06.015.
   PubMed Web of Science ®Google Scholar
• Healy D, Le Noury J, Harris M, Butt M, Linden S, Whitaker C, Zou L, Roberts AP. Mortality in schizophrenia and related psychoses: data from two cohorts, 1875-1924 and 1994-2010. BMJ Open. 2012;2(5):e001810. doi:10.1136/bmjopen-2012-001810.
   PubMed Web of Science ®Google Scholar